At Endo Pharmaceuticals we take our responsibility to patients, healthcare providers and shareholders very seriously and we are committed to fostering a company culture that supports conducting business in a compliant and ethical manner. The Compliance and Business Practices Department oversees Endo Pharmaceutical’s compliance program which is founded on the Company’s values of respect, trust and integrity and serves as a basis for a proactive and sustainable approach to ethics and compliance. For more information on Endo’s comprehensive compliance program link to Endo's Corporate Compliance & Business Practices page.
On February 21, 2014, Endo Pharmaceuticals reached a resolution of criminal and civil claims with federal and participating state authorities regarding a previously disclosed investigation concerning past US sales, marketing and promotional practices. As a part of the settlement, Endo Pharmaceuticals has entered into a Deferred Prosecution Agreement (DPA) with the United States Department of Justice for a period of up to 2 ½ years and a Corporate Integrity Agreement (CIA) with the United States Department of Health and Human Services, Office of Inspector General for a period of 5 years. The agreements build on Endo's existing comprehensive compliance program. Endo is committed to conducting our business in a compliant and ethical manner.
For more information access the following: